26.54

1.78% -0.4503

Mineralys Therapeutics Inc (MLYS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$26.99

Offen:

$25.81

24-Stunden-Volumen:

358.79K

Relative Volume:

0.28

Marktkapitalisierung:

$2.10B

Einnahmen:

Nettoeinkommen (Verlust:

$-171.36M

KGV:

-8.9719

EPS:

-2.9581

Netto-Cashflow:

$-171.37M

1W Leistung:

-0.30%

1M Leistung:

-3.95%

6M Leistung:

-28.54%

1J Leistung:

+96.37%

1-Tages-Spanne:

$25.45

$28.65

1-Wochen-Bereich:

$24.37

$31.00

52-Wochen-Spanne:

$10.44

$47.65

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Firmenname

Mineralys Therapeutics Inc

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

(888) 378-6240

Adresse

150 N. RADNOR CHESTER RD., RADNOR

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-03-12

Neueste SEC-Einreichungen

MLYS's Discussions on Twitter

Compare MLYS vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MLYS Mineralys Therapeutics Inc	26.56	2.14B	0	-171.36M	-171.37M	-2.9581
VRTX Vertex Pharmaceuticals Inc	472.70	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	744.82	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	696.88	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	311.61	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.63	31.65B	5.36B	287.73M	924.18M	2.5229

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-11	Eingeleitet	Jefferies	Hold
2024-07-10	Eingeleitet	H.C. Wainwright	Buy
2024-04-02	Eingeleitet	Goldman	Buy
2023-03-07	Eingeleitet	BofA Securities	Buy
2023-03-07	Eingeleitet	Credit Suisse	Outperform
2023-03-07	Eingeleitet	Evercore ISI	Outperform
2023-03-07	Eingeleitet	Guggenheim	Buy
2023-03-07	Eingeleitet	Stifel	Buy
2023-03-07	Eingeleitet	Wells Fargo	Overweight

Alle ansehen

Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten

09:04 AM

Stifel reiterates Buy rating on Mineralys stock, $52 target - Investing.com

09:04 AM

08:49 AM

BofA raises Mineralys Therapeutics stock price target on NDA progress - Investing.com

08:49 AM

08:31 AM

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2025 Earnings Call Transcript - Insider Monkey

08:31 AM

12:52 PM

Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Insight - GuruFocus

12:52 PM

12:17 PM

Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Ins - GuruFocus

12:17 PM

Mar 12, 2026

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - Bitget

Mar 12, 2026

Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c) - TipRanks

Mar 12, 2026

Mineralys Therapeutics Q4 Earnings Call Highlights - Yahoo Finance

Mar 12, 2026

Earnings call transcript: Mineralys Therapeutics Q4 2025 beats EPS forecast - Investing.com

Mar 12, 2026

Mineralys Therapeutics and Lorundrostat: Clinical Development, Competitive Landscape, and Regulatory Overview for Hypertension Therapy 2122273536 - Minichart

Mar 12, 2026

Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com

Mar 12, 2026

Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss - marketscreener.com

Mar 12, 2026

Experimental hypertension drug lorundrostat heads for FDA decision in Dec. 2026 - Stock Titan

Mar 12, 2026

Mineralys Therapeutics Inc options imply 6.5% move in share price post-earnings - TipRanks

Mar 12, 2026

Mineralys earnings in focus as FDA lorundrostat decision looms By Investing.com - Investing.com Australia

Mar 12, 2026

Mineralys earnings in focus as FDA lorundrostat decision looms - Investing.com

Mar 12, 2026

How Investors Are Reacting To Mineralys Therapeutics (MLYS) FDA Acceptance Of Lorundrostat Hypertension NDA - simplywall.st

Mar 12, 2026

Capital International Investors Sells 505,624 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Mar 12, 2026

Barclays PLC Has $24.79 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Mar 12, 2026

Atika Capital Management LLC Buys New Shares in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Mar 12, 2026

Mar 11, 2026

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - Yahoo Finance

Mar 11, 2026

Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail

Mar 11, 2026

Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data By Investing.com - Investing.com UK

Mar 11, 2026

Mar 10, 2026

Mineralys Shares Climb After FDA Accepts NDA for Blood Pressure Medication - Bitget

Mar 10, 2026

Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat

Mar 10, 2026

3 Reasons Not to Sleep on ResMed Stock - AOL.com

Mar 10, 2026

H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance - Investing.com UK

Mar 10, 2026

Mineralys blood pressure drug under FDA review (MLYS:NASDAQ) - Seeking Alpha

Mar 10, 2026

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap DownHere's What Happened - MarketBeat

Mar 10, 2026

Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data - Investing.com Australia

Mar 10, 2026

H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance By Investing.com - Investing.com Canada

Mar 10, 2026

Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint - Trefis

Mar 10, 2026

Why Mineralys Therapeutics Stock Is Sinking Today - TipRanks

Mar 10, 2026

Mar 09, 2026

Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA - TipRanks

Mar 09, 2026

Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea - marketscreener.com

Mar 09, 2026

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results - Bitget

Mar 09, 2026

Mineralys Therapeutics announces FDA acceptance of NDA for lorundrostat for treatment of adults with hypertension and topline Explore-Osa trial results - marketscreener.com

Mar 09, 2026

Mineralys Therapeutics Announces FDA Acceptance Of NDA For Lorundrostat For Treatment Of Adults With Hypertension And Topline Explore-Osa Trial Results - TradingView

Mar 09, 2026

Mineralys Reports Mixed Phase 2 Results for Lorundrostat - TipRanks

Mar 09, 2026

Mineralys Therapeutics Announces FDA Acceptance of NDA for - GlobeNewswire

Mar 09, 2026

Mineralys Therapeutics to Announce Fourth Quarter and Full - GlobeNewswire

Mar 09, 2026

(MLYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Mar 09, 2026

Mar 08, 2026

165,000 Shares in Mineralys Therapeutics, Inc. $MLYS Bought by Rhenman & Partners Asset Management AB - MarketBeat

Mar 08, 2026